Consequences of brand switches during the course of pediatric growth hormone treatment

Endocrine Practice

Volumn 18, Issue 3, 2012, Pages 307-316

  Grimberg, Adda ^a,b   Feudtner, Chris ^a,b   Gordon, Catherine M ^c,d  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE ANTIBODY; HUMAN GROWTH HORMONE;

ANXIETY; ARTICLE; CLINICAL PRACTICE; DRUG DOSE; DRUG SUBSTITUTION; E-MAIL; ENDOCRINOLOGIST; FRUSTRATION; HEALTH INSURANCE; HORMONE SUBSTITUTION; HUMAN; IMMUNOGENICITY; MEDICAL PRACTICE; MEDICATION ERROR; PATIENT CARE; PEDIATRICIAN; TREATMENT REFUSAL;

CHILD; COST OF ILLNESS; COST SAVINGS; DRUG COSTS; DRUG UTILIZATION; FAMILY; FORMULARIES AS TOPIC; HUMAN GROWTH HORMONE; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; INTERNET; MEDICATION ADHERENCE; PATIENT EDUCATION AS TOPIC; PATIENT SATISFACTION; PHYSICIAN'S PRACTICE PATTERNS; QUESTIONNAIRES; RECOMBINANT PROTEINS; TIME FACTORS; UNITED STATES;

EID: 84861048088     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP11217.OR     Document Type: Article

References (37)

1. Degenerative neurologic disease in patients formerly treated with human growth hormone. Report of the Committee on Growth Hormone Use of the Lawson Wilkins Pediatric Endocrine Society, May 1985. J Pediatr. 1985;107:10-12.
2. Goeddel DV, Heyneker HL, Hozumi T, et al. Direct expression in Escherichia coli of a DNA sequence coding for human growth hormone. Nature. 1979;281:544-548.
3. Olson KC, Fenno J, Lin N, et al. Purified human growth hormone from E. coli is biologically active. Nature. 1981; 293:408-411.
4. Moore JA, Rudman CG, MacLachlan NJ, Fuller GB, Burnett B, Frane JW. Equivalent potency and pharmaco-kinetics of recombinant human growth hormones with or without an N-terminal methionine. Endocrinology. 1988; 122:2920-2926.
5. Fidotti E. A history of growth hormone injection devices. J Pediatr Endocrinol Metab. 2001;14:497-501.
6. Woodcock J, Griffin J, Behrman R, et al. The FDA's assessment of follow-on protein products: A historical per-spective. Nat Rev Drug Discov. 2007;6:437-442.
7. Dudzinski DM, Kesselheim AS. Scientific and legal via-bility of follow-on protein drugs. N Engl J Med. 2008;358: 843-849.
8. R anke MB. New preparations comprising recombinant human growth hormone: Deliberations on the issue of bio-similars. Horm Res. 2008;69:22-28.
9. Hoppe W, Berghout A. Biosimilar somatropin: Myths and facts. Horm Res. 2008;69:29-30.
10. J acobsen LV, Rolan P, Christensen MS, Knudsen KM, Rasmussen MH. Bioequivalence between ready-to-use recombinant human growth hormone (rhGH) in liquid for-mulation and rhGH for reconstitution. Growth Horm IGF Res. 2000;10:93-98.
11. Charmaz K. Grounded theory: Objectivist and construc-tivist methods. In: Denzin NK, Lincoln YS, eds. Handbook of Qualitative Research. 2nd ed. Thousand Oaks, CA: Sage Publications, 2000
12. Bialer M. Generic products of antiepileptic drugs (AEDs): Is it an issue? Epilepsia. 2007;48:1825-1832.
13. Krämer G, Biraben A, Carreno M, et al. Current approaches to the use of generic antiepileptic drugs. Epilepsy Behav. 2007;11:46-52.
14. LeLorier J, Duh MS, Paradis PE, et al. Clinical conse-quences of generic substitution of lamotrigine for patients with epilepsy. Neurology. 2008;70:2179-2186.
15. Berg MJ, Gross RA, Tomaszewski KJ, Zingaro WM, Haskins LS. Generic substitution in the treatment of epi-lepsy: Case evidence of breakthrough seizures. Neurology. 2008;71:525-530.
16. Dong BJ, Brown CH. Hypothyroidism resulting from generic levothyroxine failure. J Am Board Fam Pract. 1991;4:167-170.
17. Klein I, Danzi S. Evaluation of the therapeutic efficacy of different levothyroxine preparations in the treatment of human thyroid disease. Thyroid. 2003;13:1127-1132.
18. Eisenberg M, Distefano JJ. TSH-based protocol, tablet instability, and absorption effects on L-T4 bioequivalence. Thyroid. 2009;19:103-110.
19. Zachry WM 3rd, Doan QD, Clewell JD, Smith BJ. Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes. Epilepsia. 2009;50:493-500.
20. Hansen RN, Campbell JD, Sullivan SD. Association between antiepileptic drug switching and epilepsy-related events. Epilepsy Behav. 2009;15:481-485.
21. Rudman D, Patterson JH, Gibbas DL. Responsiveness of growth hormone-deficient children to human growth hormone. Effect of replacement therapy for one year. J Clin Invest. 1973;52:1108-1112.
22. Purrello F, Vigneri R, Belfiore A, Pezzino V, Squatrito S, Polosa P. High incidence of anti-GH antibodies in subjects treated with the GH clinical preparation available in Italy. J Endocrinol Invest. 1980;3:313-315.
23. Fryklund LM, Bierich JR, Ranke MB. Recombinant human growth hormone. Clin Endocrinol Metab. 1986;15: 511-535.
24. Kaplan SL, Underwood LE, August GP, et al. Clinical studies with recombinant-DNA-derived methionyl human growth hormone in growth hormone deficient children. Lancet. 1986;1:697-700.
25. Massa G, Vanderschueren-Lodeweyckx M, Bouillon R. Five-year follow-up of growth hormone antibodies in growth hormone deficient children treated with recom-binant human growth hormone. Clin Endocrinol (Oxf). 1993;38:137-142.
26. Buzi F, Buchanan CR, Morrell DJ, Preece MA. Antigenicity and efficacy of authentic sequence recom-binant human growth hormone (somatropin): First-year experience in the United Kingdom. Clin Endocrinol (Oxf). 1989;30:531-538.
27. Bierich JR. Clinical experience with recombinant soma-tropin: German collaborative study. Acta Paediatr Scand Suppl. 1988;347:184-186.
28. Blethen SL, Allen DB, Graves D, August G, Moshang T, Rosenfeld R. Safety of recombinant deoxyribonucleic acid-derived growth hormone: The National Cooperative Growth Study experience. J Clin Endocrinol Metab. 1996; 81:1704-1710.
29. S chwarz S, Berger P, Frisch H, Moncayo R, Phillips JA 3rd, Wick G. Growth hormone blocking antibodies in a patient with deletion of the GH-N gene. Clin Endocrinol (Oxf). 1987;27:213-224.
30. Tamilvanan S, Raja NL, Sa B, Basu SK. Clinical con-cerns of immunogenicity produced at cellular levels by bio-pharmaceuticals following their parenteral administration into human body. J Drug Target. 2010;18:489-498.
31. VanGeest JB, Johnson TP, Welch VL. Methodologies for improving response rates in surveys of physicians: A sys-tematic review. Eval Health Prof. 2007;30:303-321.
32. McMahon SR, Iwamoto M, Massoudi MS, et al. Comparison of e-mail, fax, and postal surveys of pediatri-cians. Pediatrics. 2003;111:e299-e303.
33. Grava-Gubins I, Scott S. Effects of various methodologic strategies: Survey response rates among Canadian phy-sicians and physicians-in-training. Can Fam Physician. 2008;54:1424-1430.
34. Kellerman SE, Herold J. Physician response to surveys. A review of the literature. Am J Prev Med. 2001;20:61-67.
35. Dykema J, Stevenson J, Day B, Sellers SL, Bonham VL. Effects of incentives and prenotification on response rates and costs in a national web survey of physicians. Eval Health Prof. 2011;34:434-437.
36. Braithwaite D, Emery J, De Lusignan S, Sutton S. Using the internet to conduct surveys of health professionals: A valid alternative? Fam Pract. 2003;20:545-551.
37. Lee JM, Davis MM, Clark SJ, Hofer TP, Kemper AR. Estimated cost-effectiveness of growth hormone therapy for idiopathic short stature. Arch Pediatr Adolesc Med. 2006;160: 63-269.